Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction

Journal of the American College of Cardiology

Volumn 30, Issue 1, 1997, Pages 171-179

  Mak, Koon Hou ^a   Moliterno, David J ^a   Granger, Christopher B ^b   Miller, Dave P ^a   White, Harvey D ^c   Wilcox, Robert G ^d   Califf, Robert M ^b   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c GREEN LANE HOSPITAL   (New Zealand)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOLYTIC AGENT; HEPARIN; INSULIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; FEMALE; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLASMINOGEN ACTIVATORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0030795973     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00118-6     Document Type: Article

References (59)

1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population sixteen year follow-up study . Diabetes. 23:1974;105-111.
2. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J. 9:1988;259-264.
3. Abbud ZA, Shindler DM, Wilson AC, Kostis JB. Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction a statewide study . Am Heart J. 130:1995;51-58.
4. Partamian JO, Bradley RF. Acute myocardial infarction in 258 cases of diabetes immediate and five-year survival . N Engl J Med. 273:1965;456-465.
5. Czyzk A, Krolewski AS, Szablowska S, Alot A, Kopczynski J. Clinical course of myocardial infarction among diabetic patients. Diabetes Care. 3:1980;526-529.
6. Martin CA, Thompson PL, Armstrong BK, Hobbs MS, de Klerk N. Long-term prognosis after recovery from myocardial infarction a nine year follow-up of the Perth Coronary Register . Circulation. 68:1983;961-969.
7. Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol. 54:1984;718-721.
8. Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, Sobel BE. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J. 108:1984;31-37.
9. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care. 8:1985;230-234.
10. Molstad P, Nustad M. Acute myocardial infarction in diabetic patients. Acta Med Scand. 222:1987;433-437.
11. Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, Lewis SM. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol. 62:1988;665-669.
12. Singer DE, Moulton AW, Nathan DM. Diabetic myocardial infarction interaction with other preinfarction risk factors . Diabetes. 38:1989;350-357.
13. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction contribution of both coronary artery disease and diastolic left ventricular dysfunction to the adverse prognosis . J Am Coll Cardiol. 14:1989;49-57.
14. Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol. 21:1993;920-925.
15. Barbash GI, White HD, Modan M, van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic agents. J Am Coll Cardiol. 22:1993;707-713.
16. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction data from the GISSI-2 study . J Am Coll Cardiol. 22:1993;1788-1794.
17. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction results from an international trial of 41,021 patients . Circulation. 91:1995;1659-1668.
18. Second International Study on Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:535-30.
19. Lynch M, Gammage MD, Lamb P, Nattrass M, Pentecost BL. Acute myocardial infarction in diabetic patients in the thrombolytic era. Diabet Med. 11:1994;162-165.
20. Pfeffer MA, Moye LA, Braunwald E, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA. 266:1991;528-532.
21. Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients . Lancet. 343:1994;311-322.
22. Neuhaus KL, Von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase results of the rt-PA-APSAC patency study (TAPS) . J Am Coll Cardiol. 19:1992;885-891.
23. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
24. Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med. 82:1975;733-738.
25. Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction a role for plasminogen activator inhibitor? Br Heart J. 70:1993;530-536.
26. Ross J Jr., Brandenburg RO, Dinsmore RE, et al. Guidelines for coronary angiography a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Subcommittee on Coronary Angiography) . Circulation. 76:1987;963-977A.
27. Marchant B, Umachandran V, Stevenson R, Kopelman P, Timmis A. Silent myocardial ischemia role of subclinical neuropathy in patients with and without diabetes . J Am Coll Cardiol. 22:1993;1433-1437.
28. Langer A, Freeman M, Josse R, Armstrong P. Metaiodobenzylguanidine imaging in diabetes mellitus assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia . J Am Coll Cardiol. 25:1995;610-618.
29. Hjalmarson A, Gilpin EA, Nicod P, et al. Differing circadian patterns of symptom onset in subgroups of patients with acute myocardial infarction. Circulation. 80:1989;267-275.
30. Kleiman NS, Schechtmann KB, Young PM, et al. Lack of diurnal variation in the onset of non-Q wave infarction. Circulation. 81:1990;548-555.
31. Tofler GH, Muller JE, Stone PH, et al. Modifiers of timing and possible triggers of acute myocardial infarction in the TIMI II study group. J Am Coll Cardiol. 20:1992;1049-1055.
32. Zarich S, Waxman S, Freeman RT, Mittleman M, Hegarty P, Nesto RW. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol. 24:1994;956-962.
33. Gwilt DJ, Petri M, Lewis PW, Nattrass M, Pentecost BL. Myocardial infarct size and mortality in diabetic patients. Br Heart J. 54:1985;466-472.
34. Lehto S, Pyorala K, Miettinen H, et al. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Intern Med. 236:1994;291-297.
35. Orlander PR, Goff DC, Morrissey M, et al. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites the Corpus Christi Heart Project . Diabetes. 43:1994;897-902.
36. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet. 1:1989;1367-1369.
37. Califf RM, Harrelson-Woodlief L, Topol EJ. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation. 82:1990;1847-1853.
38. Takahashi N, Iwasaka T, Suguira T, et al. Left ventricular regional function after acute anterior myocardial infarction in diabetic patients. Diabetes Care. 12:1989;630-635.
39. Liu Y, Thornton JD, Cohen MV, Downey JM, Schaffer SW. Streptozocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation. 88:1993;1273-1278.
40. Sinclair-Smith BC, Opie LH. Effect of diabetic ketosis on enzyme release from isolated perfused rat hearts with experimental myocardial infarction. J Mol Cell Cardiol. 10:1978;221-234.
41. Feuvray D, Idell-Wenger JA, Neely JR. Effects of ischemia on rat myocardial function and metabolism in diabetes. Circ Res. 44:1979;322-329.
42. 2+ metabolism . Circ Res. 1988:1988;931-940.
43. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986.
44. Fava S, Azzopardi J, Muscat HA, Fenech FF. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care. 16:1993;1615-1618.
45. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis mortality and functional outcomes in the GUSTO-I trial . Circulation. 92:1995;2811-2818.
46. Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med. 327:1992;1-6.
47. Pullicino PM, Xuereb M, Aquilina J, Piedmonte MR. Stroke following acute myocardial infarction in diabetics. J Intern Med. 231:1992;287-293.
48. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction study Thrombolysis in Myocardial Infarction, phase II, pilot and clinical trial . Circulation. 83:1991;448-459.
49. Fischer VW, Barner HB, Leskiw ML. Capillary basal laminar thickness in diabetic human myocardium. Diabetes. 28:1979;713-719.
50. Soler NG, Bennett MA, Lamb P, Pentecost BL, Fitzgerald MG, Malins JM. Coronary care for myocardial infarction in diabetics. Lancet. 1:1974;475-477.
51. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis. 5:1994;767-771.
52. Dortimer AC, Shenoy PN, Shiroff RA, et al. Diffuse coronary artery disease in diabetic patients fact or fiction? Circulation. 57:1978;133-136.
53. Woodfield SL, Lundergan CF, Reiner JS, et al. Angiographic findings in diabetics treated with thrombolytic therapy after myocardial infarction [abstract]. J Am Coll Cardiol. 25 Suppl:1995;105A.
54. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 335:1996;217-225.
55. Califf RM, White H, Van de Werf F, et al. One-year results from the Global Utilization of Streptokinase and t-PA for Occluded Arteries (GUSTO-I) trial. Circulation. 94:1996;1233-1238.
56. Six-month survival in 20,981 patients with acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Eur Heart J. 13:1992;1692-1697.
57. Van de Werf F. Thrombolysis for acute myocardial infarction why is there no extra benefit after hospital discharge? Circulation. 91:1995;2862-2864.
58. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study) effects on mortality at 1 year . J Am Coll Cardiol. 26:1995;57-65.
59. Stone GW, Grines CL, Browne KF, et al. Does primary angioplasty improve prognosis of patients with diabetes and acute myocardial infarction? [abstract] . J Am Coll Cardiol. 25:(Suppl):1995;401A.